ABEONA THERAPEUTICS INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $71.2M | $-63.7M | $-54.2M | $-39.7M | $-84.9M | $-84.2M | $-76.3M | $-56.7M |
| Depreciation & Amortization | $2.5M | $2.0M | $2.3M | $3.1M | $3.3M | $4.6M | $7.8M | $2.4M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | $116.0K | $1.4M | $5.2M | $1.2M |
| Stock-Based Compensation | $10.8M | $6.6M | $4.8M | $3.1M | — | — | — | — |
| Net Cash from Operating Activities | $-76.3M | $-56.0M | $-37.0M | $-43.5M | $-65.7M | $-35.0M | $-62.8M | $-39.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $8.0M | $2.4M | $331.0K | $130.0K | $4.2M | $1.3M | $6.3M | $9.2M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $105.0M | $-39.2M | $208.0K | $-24.0M | $66.1M | $-83.7M | $60.0M | $-85.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $26.0M | $104.1M | $37.1M | $43.2M | $24.9M | $1.9M | $113.9M | $5.5M |
| Net Change in Cash | $54.7M | $8.9M | $256.0K | $-24.3M | $25.3M | $-116.8M | $111.1M | $-118.7M |
| Free Cash Flow | $-84.3M | $-58.5M | $-37.3M | $-43.6M | $-69.8M | $-36.4M | $-69.1M | $-48.4M |